Image: Laura Bratton, Photos: Post Consumer Brands (press release), Justin Sullivan (Getty Images) Rappers Snoop Dogg and Master P may have already made their mark in hip hop, but their real dream was to make cereal. Yes, cereal. Or at least that’s what the two performers (who are worth $160 million and $200 million, respectively) … Read more
A popular class of weight loss drugs may offer more lasting success than assumed, new data from Epic Research suggests. The study of medical records found that a slight majority of people who took GLP-1 drugs like semaglutide either maintained or improved their weight loss in the year after they stopped using the medication. More … Read more
The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well. While Mounjaro had already been used by some patients “off-label” for weight loss, the new FDA approval will allow the … Read more
Key Points The Health Care Select Sector SPDR Fund has dropped 3.81% in the last month and 8.03% in the past three months. Pharmaceuticals’ weak earnings reports are contributing to the healthcare sector’s recent underperformance. Bristol Myers Squibb, AbbVie, Merck, Johnson & Johnson, and Pfizer all traded below previous highs due to earnings concerns. 5 … Read more
The slim version A year ago, most people had never heard the word “Ozempic.” Now, the weight loss “wonder drug” and a nearly identical prescription called Wegovy are on the tip of everyone’s tongues. The weekly injectable, initially developed to treat Type 1 diabetes, has been hailed as a “breakthrough,” a “game-changer,” “revolutionary,” and, yes, … Read more
America’s Food Giants Confront the Ozempic Era The Wall Street Journal Source link credite
To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit Card Debts The Wall Street Journal Source link
A Louisiana woman sued the manufacturers of popular weight loss drugs Ozempic and Mounjaro on Wednesday, alleging that the drug makers failed to warn patients about the risk of severe gastrointestinal problems. The lawsuit claims that Novo Nordisk and Eli Lilly, the respective manufacturers of Ozempic and Mounjaro, “downplayed the severity of the gastrointestinal events” … Read more